CA - Arbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy Opportunity
2024-07-05 05:29:10 ET
Summary
- Arbutus Biopharma's three-pronged strategy targets cHBV by suppressing HBV DNA, reducing viral antigens, and boosting immune response.
- Imdusiran (AB-729) shows promise in Phase 2 trials, potentially leading to a functional cure for chronic hepatitis B.
- ABUS is engaged in significant IP litigation with Moderna, Pfizer, and BioNTech over LNP technology used in mRNA vaccines.
- Positive litigation outcomes could result in substantial financial compensation and enhance ABUS’s IP value.
- The Company’s strong cash position and promising clinical pipeline support its undervaluation and strong buy rating.
...
Arbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy Opportunity